# A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)

> **NCT07915609** · PHASE3 · RECRUITING · sponsor: **Pfizer** · enrollment: 756 (estimated)

## Conditions studied

- Obesity
- Overweight and/or Obesity
- Knee Osteoarthritis
- Diabetes Melliuts, Type 2

## Interventions

- **DRUG:** Berobenatide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07915609
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-10-26
- **Primary completion:** 2028-08-21
- **Final completion:** 2028-10-30
- **Target enrollment:** 756 (ESTIMATED)
- **Last updated:** 2026-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07915609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07915609, "A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)". Retrieved via MORVS 2026-11-22 from https://api.morvs.ai/clinical/NCT07915609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*
